Current Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer
Cancers · 31.12.2024 · 17 (1) · 99
DOI: 10.3390/cancers17010099 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.12.2024. Verfasst von Juan Gómez Rivas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, Hospital Clínico San Carlos, 28040 Madrid, Spain. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Localized high-risk (HR) prostate cancer (PCa) is a heterogeneous disease whose likelihood of a biochemical recurrence, metastatic progression and cancer-related mortality after initial treatment is higher when compared with patients with low (LR) or intermediate-risk (IR) disease. In the past, neoadjuvant therapy has shown an improvement in postoperative oncological variables but failed to demonstrate any survival advantages. With the promising results from novel treatments in metastatic and non-metastatic castration resistant PCa settings, new evidence has appeared in the literature in the neoadjuvant setting. Background/Objectives: To describe the current evidence for different neoadjuvant treatments before a radical prostatectomy in high-risk prostate cancer.
Methods
We performed a comprehensive English literature search for original and review articles through January–August 2024, using Pubmed, Medline and ClinicalTrials.gov databases, as well as a comprehensive review of different international guidelines, searching the following terms: “neoadjuvant ADT prostate cancer”, “neoadjuvant ADT”, “prostate cancer surgery” and “neoadjuvant high-risk prostate cancer”. We included 61 papers for the final review. Results and Discussion: Neoadjuvant therapy is not recommended in daily practice by any international guideline. The National Comprehensive Cancer Network (NCCN) guidelines strongly discourage the use of ADT as a neoadjuvant therapy outside of clinical trials. ADT + ARTAs show promising data in phase-II trials, including favorable pCR, MRD, PSA relapse and salvage therapy rates. Clinical trials on chemotherapy, 177Lu-PSMA, genomic-targeted therapies and markers of response leave room for further evidence acquisition due to their encouraging results.
Conclusions
Currently, no phase III data supports systemic neoadjuvant therapy before RP. Phase II studies show promising data for ADT with second-generation agents, including favorable pCR, MRD, PSA relapse and salvage therapy rates.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Urology Department, Hospital Clínico San Carlos, 28040 Madrid, Spain.
- Health Research Institute, Hospital Clínico San Carlos, 28040 Madrid, Spain.
- Urology, Surgery Department, Universidad Complutense de Madrid, 28040 Madrid, Spain.
- Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK.
- Urology Department, Vienna Medical University, 1090 Wien, Austria.
- Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia.
ORCID-Profile: Juan Gómez Rivas, Luis Enrique Ortega Polledo, Beatriz Gutiérrez Hidalgo, Bhaskar K Somani, Noelia Sanmamed Salgado, María Isabel Galante Romo, Jesús Moreno Sierra
Zitieren
APA
Gómez Rivas, J., Ortega Polledo, L. E., De La Parra Sánchez, I., Gutiérrez Hidalgo, B., Martín Monterrubio, J., Marugán Álvarez, M. J., Somani, B. K., Enikeev, D., Puente Vázquez, J., Sanmamed Salgado, N., Galante Romo, M. I., & Moreno Sierra, J. (2024). Current Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer. Cancers, 17(1), 99. https://doi.org/10.3390/cancers17010099
Vancouver
Gómez Rivas J, Ortega Polledo LE, De La Parra Sánchez I, Gutiérrez Hidalgo B, Martín Monterrubio J, Marugán Álvarez MJ, et al. Current Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer. Cancers. 2024;17(1):99. doi:10.3390/cancers17010099
BibTeX
@article{GmezRivas2024,
author = {Gómez Rivas, Juan and Ortega Polledo, Luis Enrique and De La Parra Sánchez, Irene and Gutiérrez Hidalgo, Beatriz and Martín Monterrubio, Javier and Marugán Álvarez, María Jesús and Somani, Bhaskar K and Enikeev, Dmitry and Puente Vázquez, Javier and Sanmamed Salgado, Noelia and Galante Romo, María Isabel and Moreno Sierra, Jesús},
title = {Current Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer},
journal = {Cancers},
year = {2024},
volume = {17},
number = {1},
pages = {99},
doi = {10.3390/cancers17010099}
}
EUVIMED